EP Patent

EP2536688A4 — Stable dosage forms of levomilnacipran

Assigned to Pierre Fabre Medicament SA · Expires 2014-04-02 · 12y expired

What this patent protects

Patent listed against levomilnacipran-hydrochloride.

Drugs covered by this patent

Patent Metadata

Patent number
EP2536688A4
Jurisdiction
EP
Classification
—
Expires
2014-04-02
Drug substance claim
No
Drug product claim
No
Assignee
Pierre Fabre Medicament SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.